Agios Announces FDA Approval of PYRUKYND® (mitapivat) as
– Approval Based on Results from ACTIVATE and ACTIVATE-T Phase 3 Studies, Supports Treatment of Adults with PK Deficiency Regardless of Transfusion Status...
Source: globenewswire.com
Stay updated with breaking news from Provide Robust Patient Access Programs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Approval Based on Results from ACTIVATE and ACTIVATE-T Phase 3 Studies, Supports Treatment of Adults with PK Deficiency Regardless of Transfusion Status...